The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: a prospective study

Yong-Hua Gao, Wei-Jie Guan, Gang Xu, Zhi-Ya Lin, Yan Tang, Zhi-Min Lin, Yang Gao, Hui-Min Li, Nan-Shan Zhong, Guo-Jun Zhang, Rong-Chang Chen, Yong-Hua Gao, Wei-Jie Guan, Gang Xu, Zhi-Ya Lin, Yan Tang, Zhi-Min Lin, Yang Gao, Hui-Min Li, Nan-Shan Zhong, Guo-Jun Zhang, Rong-Chang Chen

Abstract

Background: Although viral infections are a major cause of exacerbations in patients with chronic airway diseases, their roles in triggering bronchiectasis exacerbations in adults remain unclear. Therefore, we prospectively investigated the incidence and clinical impacts of viral infection in adults with bronchiectasis exacerbations.

Methods: The study cohort of 119 adults with bronchiectasis was followed up prospectively for 12 months. Nasopharyngeal swabs and sputum samples were assayed for 16 respiratory viruses, using polymerase chain reaction assays. Symptoms, spirometry, quality of life, bacterial cultures, and inflammatory markers were assessed during steady-state bronchiectasis and exacerbations.

Results: A total of 100 exacerbations were captured from 58 patients during 1-year follow-up. Respiratory viruses were found more frequently in nasopharyngeal swabs and sputum during bronchiectasis exacerbations (49 of 100, 49.0%) than during steady state (11 of 58, 18.9%; P < .001). The most common viruses found in patients experiencing exacerbations were coronavirus (19 of 65, 39.2%), rhinovirus (16 of 65, 24.6%), and influenza A/B viruses (16 of 65, 24.6%). Virus-positive exacerbations were associated with a greater increase in markers of systemic and airway inflammation (serum IL-6 and tumor necrosis factor-α; sputum IL-1β and tumor necrosis factor-α) compared with virus-negative exacerbations, but the differences in spirometric indexes, quality of life, and bacterial density were unremarkable. In receiver operating characteristics analysis, serum interferon-γ-induced protein 10 yielded an area under curve of 0.67 (95% CI, 0.53-0.77; P = .018). Furthermore, a greater proportion of patients with virus-positive exacerbations received IV antibiotics.

Conclusions: Prevalence of viral infections, detected by polymerase chain reaction assay, is higher in cases of bronchiectasis exacerbations than in steady-state bronchiectasis, suggesting that respiratory viruses play crucial roles in triggering bronchiectasis exacerbations. The potential mechanisms of virus-induced bronchiectasis exacerbations merit further investigations.

Trial registry: ClinicalTrials.gov; No.: NCT01801657; www.clinicaltrials.gov.

Figures

Figure 1
Figure 1
Flowchart of patient recruitment.
Figure 2
Figure 2
Detection of respiratory viruses in NPS and sputum at steady-state bronchiectasis and bronchiectasis exacerbations by polymerase chain reaction assays. **P

Figure 3

Receiver operating characteristic curve for…

Figure 3

Receiver operating characteristic curve for serum interferon-γ-induced protein 10 in predicting viral infection…

Figure 3
Receiver operating characteristic curve for serum interferon-γ-induced protein 10 in predicting viral infection at bronchiectasis exacerbation. AUC = area under the curve.
Figure 3
Figure 3
Receiver operating characteristic curve for serum interferon-γ-induced protein 10 in predicting viral infection at bronchiectasis exacerbation. AUC = area under the curve.

References

    1. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest. 2010;138(4):944–949.
    1. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(suppl 1):i1–i58. British Thoracic Society Bronchiectasis non-CF Guideline Group.
    1. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997;10(8):1754–1760.
    1. Chalmers JD, Goeminne P, Aliberti S. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–585.
    1. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565–1572.
    1. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J. 2009;33(2):312–318.
    1. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–665.
    1. Chang AB, Bilton D. Exacerbations in cystic fibrosis: 4—non-cystic fibrosis bronchiectasis. Thorax. 2008;63(3):269–276.
    1. Tunney MM, Einarsson GG, Wei L. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med. 2013;187(10):1118–1126.
    1. Ko FW, Ip M, Chan PK. Viral etiology of acute exacerbations of COPD in Hong Kong. Chest. 2007;132(3):900–908.
    1. Rohde G, Wiethege A, Borg I. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003;58(1):37–42.
    1. Johnston SL, Pattemore PK, Sanderson G. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ. 1995;310(6989):1225–1229.
    1. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ. 1993;307(6910):982–986.
    1. Asner S, Waters V, Solomon M. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros. 2012;11(5):433–439.
    1. Flight WG, Bright-Thomas RJ, Tilston P. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax. 2014;69(3):247–253.
    1. Kapur N, Mackay IM, Sloots TP, Masters IB, Chang AB. Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children. Arch Dis Child. 2014;99(8):749–753.
    1. Mallia P, Footitt J, Sotero R. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(11):1117–1124.
    1. Bafadhel M, McKenna S, Terry S. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671.
    1. National Institutes of Health Clinical Center, The prevalence and impact of depression and anxiety symptoms in patients with non-CF bronchiectasis. NCT01688180, National Institutes of Health Bethesda, MD, Updated August 6, 2013, 2012.
    1. Tsang KW, Ho PL, Lam WK. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158(3):723–727.
    1. Pasteur MC, Helliwell SM, Houghton SJ. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4 pt 1):1277–1284.
    1. Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009;34(1):125–131.
    1. Tsang KW, Chan K, Ho P. Sputum elastase in steady-state bronchiectasis. Chest. 2000;117(2):420–426.
    1. Liu WK, Chen DH, Liu Q. Detection of human bocavirus from children and adults with acute respiratory tract illness in Guangzhou, southern China. BMC Infect Dis. 2011;11:345.
    1. Seemungal T, Harper-Owen R, Bhowmik A. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618–1623.
    1. Sykes A, Edwards MR, Macintyre J. Rhinovirus 16-induced IFN-alpha and IFN-beta are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol. 2012;129(6):1506–1514.
    1. Sykes A, Macintyre J, Edwards MR. Rhinovirus-induced interferon production is not deficient in well controlled asthma. Thorax. 2014;69(3):240–246.
    1. Edwards MR, Regamey N, Vareille M. Impaired innate interferon induction in severe therapy resistant atopic asthmatic children. Mucosal Immunol. 2013;6(4):797–806.
    1. Chan SC, Shum DK, Tipoe GL, Mak JC, Leung ET, Ip MS. Upregulation of ICAM-1 expression in bronchial epithelial cells by airway secretions in bronchiectasis. Respir Med. 2008;102(2):287–298.
    1. Sajjan US, Jia Y, Newcomb DC. H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J. 2006;20(12):2121–2123.
    1. Quittner AL, Marciel KK, Salathe MA. A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest. 2014;146(2):437–448.
    1. Rowan SA, Bradley JM, Bradbury I. Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med. 2014;189(5):586–592.
    1. Quint JK, Donaldson GC, Goldring JJ, Baghai-Ravary R, Hurst JR, Wedzicha JA. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest. 2010;137(4):812–822.
    1. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only) Cochrane Database Syst Rev. 2012;4:CD002744.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir